|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001.PubMed/NCBI
|
|
4
|
Sotiriou C, Neo SY, McShane LM, et al:
Breast cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim E and Winer EP: Adjuvant chemotherapy
in luminal breast cancers. Breast. 20(Suppl 3): S128–S131. 2011.
View Article : Google Scholar
|
|
6
|
Paridaens R, Biganzoli L, Bruning P, et
al: Paclitaxel versus doxorubicin as first-line single-agent
chemotherapy for metastatic breast cancer: a European Organization
for Research and Treatment of Cancer Randomized Study with
cross-over. J Clin Oncol. 18:724–733. 2000.PubMed/NCBI
|
|
7
|
Sledge GW, Neuberg D, Bernardo P, Ingle
JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of
doxorubicin, paclitaxel, and the combination of doxorubicin and
paclitaxel as front-line chemotherapy for metastatic breast cancer:
an intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghersi D, Wilcken N and Simes RJ: A
systematic review of taxane-containing regimens for metastatic
breast cancer. Br J Cancer. 93:293–301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Henderson IC, Berry DA, Demetri GD, et al:
Improved outcomes from adding sequential paclitaxel but not from
escalating doxorubicin dose in an adjuvant chemotherapy regimen for
patients with node-positive primary breast cancer. J Clin Oncol.
21:976–983. 2003. View Article : Google Scholar
|
|
10
|
Varghese S and Rabkin SD: Oncolytic herpes
simplex virus vectors for cancer virotherapy. Cancer Gene Ther.
9:967–978. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Todo T, Martuza RL, Rabkin SD and Johnson
PA: Oncolytic herpes simplex virus vector with enhanced MHC class I
presentation and tumor cell killing. Proc Natl Acad Sci USA.
98:6396–6401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukuhara H, Martuza RL, Rabkin SD, Ito Y
and Todo T: Oncolytic herpes simplex virus vector g47delta in
combination with androgen ablation for the treatment of human
prostate adenocarcinoma. Clin Cancer Res. 11:7886–7890. 2005.
View Article : Google Scholar
|
|
13
|
Wang JN, Hu P, Zeng MS and Liu RB:
Anti-tumor effect of oncolytic herpes simplex virus G47delta on
human nasopharyngeal carcinoma. Chin J Cancer. 30:831–841. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu R, Varghese S and Rabkin SD: Oncolytic
herpes simplex virus vector therapy of breast cancer in C3(1)/SV40
T-antigen transgenic mice. Cancer Res. 65:1532–1540. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petrowsky H, Roberts GD, Kooby DA, et al:
Functional interaction between fluorodeoxyuridine-induced cellular
alterations and replication of a ribonucleotide reductase-negative
herpes simplex virus. J Virol. 75:7050–7058. 2001. View Article : Google Scholar
|
|
16
|
Eisenberg DP, Adusumilli PS, Hendershott
KJ, et al: 5-fluorouracil and gemcitabine potentiate the efficacy
of oncolytic herpes viral gene therapy in the treatment of
pancreatic cancer. J Gastrointest Surg. 9:1068–1077. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bennett JJ, Adusumilli P, Petrowsky H, et
al: Up-regulation of GADD34 mediates the synergistic anticancer
activity of mitomycin C and a gamma134.5 deleted oncolytic herpes
virus (G207). FASEB J. 18:1001–1003. 2004.PubMed/NCBI
|
|
18
|
Aghi M, Rabkin S and Martuza RL: Effect of
chemotherapy-induced DNA repair on oncolytic herpes simplex viral
replication. J Natl Cancer Inst. 98:38–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu R, Martuza RL and Rabkin SD:
Intracarotid delivery of oncolytic HSV vector G47Delta to
metastatic breast cancer in the brain. Gene Ther. 12:647–654. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Hu P, Zeng M, Rabkin SD and Liu R:
Oncolytic herpes simplex virus treatment of metastatic breast
cancer. Int J Oncol. 40:757–763. 2012.PubMed/NCBI
|
|
21
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elliott G and O’Hare P: Herpes simplex
virus type 1 tegument protein VP22 induces the stabilization and
hyperacetylation of microtubules. J Virol. 72:6448–6455.
1998.PubMed/NCBI
|
|
23
|
Kim WY, Woo SU, Seo JH, Son GS, Lee JB and
Bae JW: Toxicities, dose reduction and delay of docetaxel and
paclitaxel chemotherapy in breast cancer without distant
metastases. J Cancer Res Ther. 7:412–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loibl S, Skacel T, Nekljudova V, et al:
Evaluating the impact of Relative Total Dose Intensity (RTDI) on
patients’ short and long-term outcome in taxane- and
anthracycline-based chemotherapy of metastatic breast cancer- a
pooled analysis. BMC Cancer. 12:121–131. 2011.PubMed/NCBI
|
